BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Meazza C, Asaftei SD. State-of-the-art, approved therapeutics for the pharmacological management of osteosarcoma. Expert Opin Pharmacother 2021;:1-12. [PMID: 34058096 DOI: 10.1080/14656566.2021.1936499] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Van Stiphout CM, Luu AK, Viloria-petit AM. Proteasome Inhibitors and Their Potential Applicability in Osteosarcoma Treatment. Cancers 2022;14:4544. [DOI: 10.3390/cancers14194544] [Reference Citation Analysis]
2 Georgiou M, Ntavelou P, Stokes W, Roy R, Maher GJ, Stoilova T, Rakhit CP, Martins M, Ajuh P, Horowitz N, Berkowitz RS, Elias K, Seckl MJ, Pardo OE. ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma. Oncogene 2022. [PMID: 35301407 DOI: 10.1038/s41388-022-02251-8] [Reference Citation Analysis]
3 Hu X, Deng K, Ye H, Sun Z, Huang W, Sun Y, Yan W. Trends in Tumor Site-Specific Survival of Bone Sarcomas from 1980 to 2018: A Surveillance, Epidemiology and End Results-Based Study. Cancers (Basel) 2021;13:5381. [PMID: 34771548 DOI: 10.3390/cancers13215381] [Reference Citation Analysis]
4 Li YJ, Wu JY, Liu J, Xu W, Qiu X, Huang S, Hu XB, Xiang DX. Artificial exosomes for translational nanomedicine. J Nanobiotechnology 2021;19:242. [PMID: 34384440 DOI: 10.1186/s12951-021-00986-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]